A wireless bioimpedance device for abdominal fatness monitoring

n/

OPTICALLY INDUCED F CENTRE-INTERSTITIAL RECOMBINATION IN GAMMA IRRADIATED KCl

It is known that when gamma irradiated KCl crystals are illuminated with F light they show a luminescence with its maximum at about 440 nm. The same emission band appears in the thermoluminescence of these samples from LNT to 300 °C. Several KCl samples were gamma irradiated at room temperature. Afterwards they were heated at 100 °C till no light at 440 nm was observed. They were then cooled down to room temperature. Each sample was illuminated with F light during some interval of time, a different interval for each sample. While this was made, the variation of the F centre concentration and the light intensity were simultaneously measured. After this bleaching interval, the thermoluminescence of the sample up to 350 °C was obtained. It was found that the area (AF) under the photoluminescence Gurve and the area (AT) under the thermoluminescence curve verify AF/β + AT/α = F0 + 2 M0. It has been concluded that this photoluminescence is due to the recombination of F centres which are mobile under illumination with trapped interstitials. This light emission at 440 nm has been used to detect optically induced F centre migration in several experiments. The results support Lüty's proposal that the F* center is the mobile entity

Manejo médico-quirúrgico de las lesiones traqueobronquiales traumáticas no iatrogénicas

Objetivo: Describir el manejo médico-quirúrgico de las lesiones traqueobronquiales traumáticas no iatrogénicas. Pacientes y método: De enero de 1993 a julio de 2004 se registraron en nuestro servicio 15 casos de lesiones traqueobronquiales traumáticas. En todos los pacientes el diagnóstico se estableció por broncoscopia y a todos se le realizó una tomografía computarizada de tórax. Se eligió tratamiento quirúrgico cuando había inestabilidad vital del paciente, herida traqueal abierta, lesiones esofágicas asociadas, progresión de enfisema subcutáneo o mediastínico, mediastinitis o colecciones mediastínicas sospechosas en pruebas de imagen o dificultades en la ventilación mecánica por la lesión traqueobronquial traumática. Resultados: La edad media (± desviación estándar) de los pacientes fue de 35,5 ± 18,9 años y 12 (80%) eran varones. Se registraron 13 traumatismos cerrados (86,7%) y 2 abiertos (13,3%). La localización más frecuente de la lesión fue bronquial (9 casos; 60%), seguida de tráquea cervical (4 casos; 26,6%) y tráquea toracicobronquial (2 casos; 13,4%). El síntoma inicial más frecuente fue el enfisema subcutáneo, que presentaron 11 pacientes (73,3%). Las lesiones asociadas más frecuentes fueron torácicas, con 12 casos (86,7%), seguidas de ortopédicas, con 9 (60%). El tratamiento de elección fue quirúrgico en 11 casos (73,3%) y médico conservador en 4 (26,7%). Falleció una paciente tratada de forma conservadora por lesión cerebral irreversible. Conclusiones: Las lesiones traqueobronquiales pueden tratarse de forma conservadora si cumplen criterios estrictos de selección. El tamaño o la localización no debe ser un criterio para la elección del tratamiento quirúrgico

Trends in Targeted Therapy Usage in Inflammatory Bowel Disease : TRENDY Study of ENEIDA

Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life treatment usage. For this purpose, patients from the ENEIDA registry who received their first targeted IBD treatment (biologics or tofacitinib) between 2015 and 2021 were included. A subsequent analysis with Machine Learning models was performed. The study included 10,009 patients [71% with Crohn's disease (CD) and 29% with ulcerative colitis (UC)]. In CD, anti-TNF (predominantly adalimumab) were the main agents in the 1st line of treatment (LoT), although their use declined over time. In UC, anti-TNF (mainly infliximab) use was predominant in 1st LoT, remaining stable over time. Ustekinumab and vedolizumab were the most prescribed drugs in 2nd and 3rd LoT in CD and UC, respectively. Overall, the use of biosimilars increased over time. Machine Learning failed to identify a model capable of predicting treatment patterns. In conclusion, drug positioning is different in CD and UC. Anti-TNF were the most used drugs in IBD 1st LoT, being adalimumab predominant in CD and infliximab in UC. Ustekinumab and vedolizumab have gained importance in CD and UC, respectively. The approval of biosimilars had a significant impact on treatment